Dec
4
2019
On demand

In-depth case study webinar: how MolMed achieved large-scale GMP production of LV and RV Vectors

Case study: MolMed presents process development and large-scale GMP production for lentiviral (LV) and retroviral (RV) vectors in the iCELLis® 500 fixed-bed bioreactor

MolMed is a biotechnology company focused on research, development and manufacturing of innovative therapies to treat cancer and rare genetic diseases. MolMed has developed a robust and scalable process for the industrial scale production of both LV and RV vectors for use in gene-modified cell therapy using the iCELLis bioreactor platforms.

Molmed present the development and optimization of their LV and RV vector production processes in the scale down iCELLis nano bioreactor. The processes were then scaled up to the production scale iCELLis 500 bioreactor and results were comparable to processes performed at small scale.

Webinar participants learn:

  • How an iCELLis bioreactor can used for commercial scale vector production
  • MolMed’s process development and large-scale production process using the iCELLis platform
  • How to develop industrial scale viral vector production

Dr Giuliana Vallanti
Director, Development and Global R&D, Cell and Gene, AGC Biologics
Clive Glover
Director, Strategy at Pall Biotech

SPEAKERS

Dr Giuliana Vallanti
Director, Development and Global R&D, Cell and Gene, AGC Biologics
Clive Glover
Director, Strategy at Pall Biotech

You might also like

Accelerating cell therapy discovery & development with non-viral gene...

D Hermanson
X Patrinostro
David Hermanson
David Hermanson
Senior Manager of R&D Applications, Cell and Gene Therapy at Bio-techne
Xiaobai Patrinostro
Xiaobai Patrinostro
Manager of Genome Engineering Services, Cell and Gene Therapy at Bio-techne
16 Jun 2022
29
Days
16
Hrs
24
Min
Register

Applying an HPLC analytical platform for mRNA process monitoring

N Pavlin
Nejc Pavlin
Nejc Pavlin
Project Manager in Process Analytics Development at BIA Separations
7 Jun 2022
21
Days
8
Hrs
24
Min
Register

Optimizing E. Coli cell growth performance with in-line, real-time OD600...

T Buch
R Shanbaky
Tanja Buch
Tanja Buch
Technical Director at Biifactory Competence Center
Ramsey  Shanbaky
Ramsey Shanbaky
Bioprocess Applications Manger at C Technologies, Inc - a Repligen Company
1 Jun 2022
14
Days
16
Hrs
24
Min
Register

Manufacturing considerations for viral and non-viral platform selection

V Slepushkin,
A Noyes,
A Hagerman et al.
Vladimir Slepushkin
Vladimir Slepushkin
Global Head of Manufacturing at MedTherapy Biotech
Aaron Noyes
Aaron Noyes
Vice President of Development at Codiak Biosciences
Allison Hagerman
Allison Hagerman
Vice President, Product Development, Oncolytics Biotech
Laurens  Sierkstra
Laurens Sierkstra
Senior Director, Business Leader, Purification at Thermo Fisher Scientific
10 May 2022
Watch now

From cells to purified capsids: How to develop a scalable rAAV process

Å Hagner McWhirter
Åsa Hagner McWhirter
Åsa Hagner McWhirter
Principal Scientist at Cytiva
3 May 2022
Watch now